Galectin Therapeutics
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
/ 
Frequently asked questions
To buy Galectin Therapeutics stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Galectin Therapeutics by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Galectin Therapeutics is GALT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Galectin Therapeutics has its primary listing on NASDAQ (Small cap). You can trade Galectin Therapeutics with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Galectin Therapeutics is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Galectin Therapeutics as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Galectin Therapeutics.